Advertising and promotion of reimbursement for medical devices

On Tuesday 22 February I delivered this presentation at the Q1 2nd Annual European Medical Devices Reimbursement Conference.

My presentation addressed the question of what constraints there are on companies providing information with respect to coverage and reimbursement to customers. There are many, both contained in mandatory law and self-regulatory rules.

It was remarkable to hear how similar and at the same time different national reimbursement systems are in the EU, as for medical devices no harmonisation has taken place yet in the field of reimbursement. For pharmaceuticals there is some in the form of the Transparency Directive. However, the upcoming Cross-Border Healthcare Directive is expected to lead to de facto harmonisation in the field of medical devices as it provides for a legal basis for HTA cooperation, as you will also see explained in brief in my presentation.

Navigate through our knowledgebase

Related articles


Life Sciences Podcast

Axon Lawyers is a proud partner of Leaders in Life Sciences Podcast. Subscribe and listen to the upcoming inspiring stories!



More on placing on the market

After my blog about guidance document MDCG 2021-27 in which I argued why in my view it defines placing on the market wrongly by requiring transfer of a property right as a…

Read more


MDCG 2021-27 Q&A on importers and distributors – sort of box of chocolates

Life, as they say, is like a box of chocolates: you never know what you’re going to get. MDCG guidance documents are very much like that too. Even if you’ve seen them…

Read more